“Italy is historically one of the strategic research and production hubs of GSK’s drugs and vaccines. GSK’s five-year investment commitment is significant, which sees an expected total of 800 million euros in the period 2020-2025, of which 59% is intended for vaccines and 41% for drugs, while 14% of the total goes to research alone.” Fabio Landazabal, president and CEO of GSK Italia, told Adnkronos Salute on the sidelines of a conference promoted by GSK – today and tomorrow in Rome (Auditorium della Tecnica) – with over 200 Italian pulmonologists gathered to take stock of the new therapies provision for respiratory diseases, first of all asthma which affects 4-8% of the general population, and COPD which affects 10-11% of Italians, but with peaks of up to 15-20% among the over 65s.
“In Italy – he underlines – we are present with global biotechnological manufacturing plants for prevention and for the development of advanced therapies. We also have a unique research center in the world for vaccines and One Health, precisely to contribute to the global well-being. All this commitment allows us to attract investments of 800 million, balanced between prevention and therapy. So Italy is a unique position and we are very proud to be in this country.”
#Landazabal #GSK #Italy #investments #million
